Aug 09, 2023 / 12:00PM GMT
Sumant Kulkarni - Canaccord Genuity LLC - Analyst
Good morning, everyone. I'm Sumant Kulkarni, one of the senior biotech analysts here at Canaccord Genuity, and I'm pleased to welcome all of you to our 43rd Annual Growth Conference. I'm very happy to kick it off with Cara Therapeutics here today.
It's very interesting company. They have a product that's out in the market already sold by a partner, and also a product that's in development that has a lot of things going on that we should probably be focusing on here.
I'll turn it over to Chris Posner, the CEO; and then we also have Ryan Maynard, the CFO; and CMO, Jo Goncalves. And in the audience, we have Chief Strategy Officer, Iris Francesconi. So with that, Chris, thanks a lot for making it and thank you, everyone, for tuning in on the webcast as well.
Chris Posner - Cara Therapeutics, Inc. - CEO, President, & Director
Yeah, Sumant. Thanks for having us this morning.
Sumant Kulkarni - Canaccord Genuity LLC - Analyst
So if you want to give a few
Cara Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Mar 02, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers